FOLH1 and neoplasm: Nevertheless, the compound shows both PSMA-dependent tumor uptake and PSMA-independent and pamidronate driven uptake into bone tissue and a remarkably high tumor-to-blood as well as bone-to-blood-ratio after 24 h.